Dallas, Texas 03/12/2014 (FINANCIALSTRENDS) – Merck & Co., Inc.(NYSE:MRK) a global health care company recently shared it results on its investigational house dust mite sublingual immunotherapy tablet (MK-8237) which is currently at mid-stage clinical trial. The company presented this data during 2014 Annual Meeting of the AmericanAcademy of Allergy, Asthma & Immunology (AAAAI) in San Diego for the first time. Around 124 patents with age group of 18 and over participated in the clinical trials. According to the reports, MK-8237 was significantly effective in reducing nasal symptoms by 49% with higher dose and 27% with lower dose. The company is currently waiting U.S. approval decisions for regular production and distribution in the market.
Merck Presents more details on Tablet MK-3641 at Annual Meeting of the American Academy of Allergy, Asthma & Immunology
According to the reports, the company also shared some details pertaining to Tablet MK-3641 with respect to Monosensitized and Polysensitized Subjects, Rescue Medication Use, its efficiencies and safety at AAAAI meet. The company with their continuous focus on innovative health solutions currently operates from more than 140 countries across the world. They are also known as MSD outside US and Canada.
Merck Witness Positive Results in Hepatitis C Drugs
According to the latest reports, hepatitis C drug that is being developed by Merck & Co showed a very positive results in treating liver diseases among folks who are infected with HIV. This data is from the mid-stage clinical trials. The company also reported that the latest antiviral drugs MK-5172 and MK-8742 were tested on 29 patents over 12 week period. After the trial period, it was observed hepatitis C virus was not visible on 26 of them. This result will be major boost for treating folks who are co-infected with HIV and hepatitis C (HCV).
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.